2023-08-30 10:38:05 ET
More on Alkermes
- Alkermes: A Complicated Story Right Now
- Lybalvi: Weighing In Light, But Tipping Alkermes' Scales
- Alkermes plc 2023 Q2 - Results - Earnings Call Presentation
- Alkermes plc ( ALKS ) Q2 2023 Earnings Call Transcript
- Alkermes falls as activist holder Sarissa Capital cuts stake
- Alkermes, Sarissa offer dueling letters to shareholders (updated)
- Alkermes lifts outlook after arbitration payment from Johnson & Johnson
- Alkermes Non-GAAP EPS of $0.01 beats by $0.02, revenue of $287.6M beats by $6.41M
- Seeking Alpha’s Quant Rating on Alkermes
- Earnings data for Alkermes
- Dividend for Alkermes
For further details see:
Alkermes to grant Teva license for generic Vivitrol, settles litigation